Fig. 1.

Mast cells impair the efficacy of AAT. a Subcutaneously growing Panc02 tumors. Cells were injected into the flanks of C57Bl/6J (WT) or MC-deficient (Wsh) mice and the animals received treatment with placebo or 20 mg/kg DC101 (n = 8/8/5/5; *p < 0.05; two-way ANOVA). b Weight of end-stage Panc02 tumors at day of euthanasia (n = 8/8/5/5; *p < 0.05; one-way ANOVA). c Subcutaneously growing EL4 tumors. Cells were injected into the flanks of C57Bl/6J (WT) or MC-deficient (Wsh) mice and the animals received treatment with placebo or 20 mg/kg DC101 (n = 5/5/5/5; *p < 0.05; two-way ANOVA). d Weight of end-stage EL4 tumors at day of euthanasia (n = 5/5/5/5; *p < 0.05; one-way ANOVA). e, f Kinetic (e) or end-stage (f) tumor volume of subcutaneously growing Panc02 tumors with or without adoptive transfer of MC. After randomization animals received treatment with placebo or 20 mg/kg DC101 (n = 9/9/7/6/7/5; *p < 0.05; two-way ANOVA and one-way ANOVA). Results are shown as representative means ± s.e.m